359 related articles for article (PubMed ID: 18300756)
1. Novel strategies for relapsed and refractory acute myeloid leukemia.
Mato AR; Morgans A; Luger SM
Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
[TBL] [Abstract][Full Text] [Related]
2. Sequential continuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute myeloid leukemia patients.
Camera A; Rinaldi CR; Palmieri S; Cantore N; Mele G; Mettivier V; Miraglia E; Mastrullo L; Grimaldi F; Luciano L; Guerriero A; Rotoli B; Ferrara F
Ann Hematol; 2009 Feb; 88(2):151-8. PubMed ID: 18709502
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
Ferrara F; Palmieri S; Mele G
Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
[TBL] [Abstract][Full Text] [Related]
4. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
5. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
6. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
7. Progress and strategies for patients with relapsed and refractory acute myeloid leukemia.
Litzow MR
Curr Opin Hematol; 2007 Mar; 14(2):130-7. PubMed ID: 17255790
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party.
Ferrara F; Fazi P; Venditti A; Pagano L; Amadori S; Mandelli F
Hematol Oncol; 2008 Jun; 26(2):104-7. PubMed ID: 18271064
[TBL] [Abstract][Full Text] [Related]
9. [Recent progress in the treatment of hematological malignancies. II. Chemotherapy of relapsed and refractory acute myeloid leukemia in adult].
Ohshima T
Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):774-80. PubMed ID: 2794659
[No Abstract] [Full Text] [Related]
10. More on the treatment of relapsed acute myeloid leukemia.
Capizzi RL
Oncology (Williston Park); 1989 Oct; 3(10):72-4. PubMed ID: 2701211
[No Abstract] [Full Text] [Related]
11. Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.
Jamieson K; Odenike O
Expert Opin Pharmacother; 2012 Oct; 13(15):2171-87. PubMed ID: 22971003
[TBL] [Abstract][Full Text] [Related]
12. Consolidation therapy: what should be the standard of care?
Rowe JM
Best Pract Res Clin Haematol; 2008 Mar; 21(1):53-60. PubMed ID: 18342812
[TBL] [Abstract][Full Text] [Related]
13. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.
Perl AE; Kasner MT; Tsai DE; Vogl DT; Loren AW; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Frey NV; Nasta SD; Hexner EO; Dierov JK; Swider CR; Bagg A; Gewirtz AM; Carroll M; Luger SM
Clin Cancer Res; 2009 Nov; 15(21):6732-9. PubMed ID: 19843663
[TBL] [Abstract][Full Text] [Related]
15. Cloretazine for the treatment of acute myeloid leukemia.
Vey N; Giles F
Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
18. Emerging treatment strategies for acute myeloid leukemia (AML) in the elderly.
Kuendgen A; Germing U
Cancer Treat Rev; 2009 Apr; 35(2):97-120. PubMed ID: 18951721
[TBL] [Abstract][Full Text] [Related]
19. Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.
Montillo M; Ricci F; Tedeschi A; Cafro AM; Nosari AM; Nichelatti M; Marbello L; Morra E
Leuk Res; 2009 Aug; 33(8):1072-8. PubMed ID: 19187960
[TBL] [Abstract][Full Text] [Related]
20. Biology and management of relapsed acute myeloid leukaemia.
Craddock C; Tauro S; Moss P; Grimwade D
Br J Haematol; 2005 Apr; 129(1):18-34. PubMed ID: 15801952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
